Search - tctmd.com

Displaying 1 - 20 of 79

Sort: Relevancy | Date

News Conference News TCT 2025

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

Caitlin E. Cox

October 28, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

Presentation TCT 2024

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

Presenter: Hongbo Yang

October 30, 2024

Presentation TCT 2024

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

Presenter: Woo Jin Jang

October 27, 2024

Presentation TCT 2024

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

Presenter: Yao Jiang

October 27, 2024

Presentation TCT 2024

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Presenter: IFTIKHAR CH

October 27, 2024

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

L.A. McKeown

October 31, 2023

Presentation TCT 2023

TCT 781: Clinical outcomes of patients treated using 1-month dual antiplatelet therapy after biodegradable-polymer DES implantation

Presenter: Masaru Ishida

October 26, 2023

Presentation TCT 2023

TCT 706: 3-6 Month vs 12 Month Dual Antiplatelet Therapy After Drug Eluting Stent Placement: An Updated Meta-Analysis

Presenter: Aakash Garg

October 25, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Todd Neale

October 25, 2023

Presentation TCT 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presenter: Seong Huan Choi

October 25, 2023

Presentation TCT 2023

TCT 603: Single versus Dual Antiplatelet Therapy for Conservatively Managed Spontaneous Coronary Artery Dissection (SCAD) Patients

Presenter: Sophie Offen

October 25, 2023

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

Presentation TCT 2023

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

Presenter: Myeong-Ki Hong

October 25, 2023

Presentation TCT 2023

TCT 7: Strategy of Dual Antiplatelet Therapy for Patients With ST elevation myocardial infarction or Non-ST elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis

Presenter: Toshiki Kuno

October 24, 2023

Presentation TCT 2023

Dual Antiplatelet Therapy After PCI: Considerations for Duration and Choice Of Drug(s)

Presenter: Jacqueline Tamis-Holland

October 24, 2023

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Todd Neale

September 21, 2022

Advertisement

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

What’s Going to Be Hot at TCT 2025

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

TCT 781: Clinical outcomes of patients treated using 1-month dual antiplatelet therapy after biodegradable-polymer DES implantation

TCT 706: 3-6 Month vs 12 Month Dual Antiplatelet Therapy After Drug Eluting Stent Placement: An Updated Meta-Analysis

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

TCT 603: Single versus Dual Antiplatelet Therapy for Conservatively Managed Spontaneous Coronary Artery Dissection (SCAD) Patients

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

TCT 7: Strategy of Dual Antiplatelet Therapy for Patients With ST elevation myocardial infarction or Non-ST elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis

Dual Antiplatelet Therapy After PCI: Considerations for Duration and Choice Of Drug(s)

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content